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Abstract
Background:	Hypertension	(high	blood	pressure)	is	a	common	long-	term	health	con-
dition.	 Patient	 involvement	 in	 treating	 and	 monitoring	 hypertension	 is	 essential.	
Control	of	hypertension	improves	population	cardiovascular	outcomes.	However,	for	
an	individual,	potential	benefits	and	harms	of	treatment	are	finely	balanced.	Shared	
decision	making	has	the	potential	to	align	decisions	with	the	preferences	and	values	
of	patients.
Objective:	Determine	the	effectiveness	of	interventions	to	support	shared	decision	
making	in	hypertension.
Search strategy:	 Searches	 in	 MEDLINE,	 EMBASE,	 CINAHL,	Web	 of	 Science	 and	
PsycINFO	up	to	30	September	2017.
Eligibility criteria:	 Controlled	 studies	 evaluating	 the	 effects	 of	 shared	 decision-	
making	interventions	for	adults	with	hypertension	compared	with	any	comparator	in	
any	setting	and	reporting	any	outcome	measures.
Results:	Six	studies	(five	randomized	controlled	trials)	in	European	primary	care	were	
included.	Main	 intervention	 components	were	 as	 follows:	 training	 for	 health-	care	
professionals,	decision	aids,	patient	coaching	and	a	patient	leaflet.	Four	studies,	none	
at	low	risk	of	bias,	reported	a	measure	of	shared	decision	making;	the	intervention	
increased	shared	decision	making	in	one	study.	Four	studies	reported	blood	pressure	
between	6	months	 and	 3	years	 after	 the	 intervention;	 there	was	 no	 difference	 in	
blood	pressure	between	intervention	and	control	groups	in	any	study.	Lack	of	com-
parability	between	studies	prevented	meta-	analysis.
Conclusions:	Despite	widespread	calls	for	shared	decision	making	to	be	embedded	in	
health	care,	there	is	little	evidence	to	inform	shared	decision	making	for	hyperten-
sion,	one	of	the	most	common	conditions	managed	in	primary	care.
K E Y W O R D S
hypertension,	patient	participation,	primary	health	care,	shared	decision	making,	systematic	
review
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1  | BACKGROUND
Shared	 decision	 making	 is	 a	 process	 by	 which	 clinicians	 and	 pa-
tients	work	together	to	make	health-	care	choices,	based	on	clinical	
evidence	and	the	patient’s	 informed	preferences.1	Shared	decision	
making	 is	 viewed	 as	 an	 ethical	 imperative	 by	 health-	care	 profes-
sional	regulatory	bodies2	and	is	embedded	in	health	policy	in	several	
countries,	including	the	UK	and	the	United	States.3,4	It	is	increasingly	
advocated	in	the	care	of	all	conditions,	including	chronic	health-	care	
conditions	such	as	hypertension	(high	blood	pressure)5	Implementing	
shared	decision	making	in	routine	care	has	proven	challenging,	and	
many	 barriers	 have	 been	 identified	 from	both	 patient	 and	 health-	
care	professional	perspectives.6,7
Interventions	 to	support	 shared	decision	making	 include	 those	
which	prepare	health-	care	teams,	individual	clinicians	or	patients	be-
fore	consultations	(e.g	patient	coaching	interventions,	decision	aids,	
clinician	or	health-	care	team	training	interventions),	and	those	which	
help	practitioners	and	patients	make	decisions	together	during	con-
sultations,	notably	decision	aids.	There	is	evidence	from	conditions	
other	 than	 hypertension	 that	 shared	 decision	making	 can	 lead	 to	
more	appropriate	care,8	reduce	overtreatment,9	improve	health	out-
comes10	and	may	reduce	health-	care	treatment	costs.11	A	systematic	
review	of	interventions	to	support	the	adoption	of	shared	decision	
making	 by	 health	 professionals12	 was	 unable	 to	 draw	 conclusions	
about	 the	most	 effective	 interventions	 for	 supporting	 health	 pro-
fessionals’	adoption	of	shared	decision	making,	due	to	the	paucity	of	
evidence.	None	of	the	studies	in	that	review	focused	on	people	with	
hypertension.	A	recent	systematic	review	of	randomized	controlled	
trials,	 including	one	study	that	did	focus	on	hypertension	manage-
ment,	found	that	people	exposed	to	decision	aids	feel	more	knowl-
edgeable,	clearer	about	their	values	and	may	make	choices	more	in	
line	with	their	values.8
Hypertension	 affected	 31%	 of	 the	world’s	 adult	 population	 in	
201013;	 it	 increases	 the	 risk	 of	 cardiovascular	 conditions	 such	 as	
strokes	 and	heart	 attacks	 and	 is	 the	 leading	preventable	 cause	of	
premature	 death	 worldwide.14	 Observational	 studies	 show	 a	 pro-
gressive	 rise	 in	 cardiovascular	 risk	 as	 systolic	 blood	pressure	 rises	
above	 115	mmHg.15	 Hypertension	 is	 diagnosed	 when	 a	 person’s	
blood	pressure	(BP)	exceeds	a	threshold,	typically	140/90	mmHg.16 
Management	 is	 characterized	 by	 monitoring	 of	 blood	 pressure	
alongside	other	cardiovascular	 risk	 factors	and	 the	use	of	 lifestyle	
measures,	usually	 combined	with	antihypertensive	drug	 treatment	
to	 reduce	 blood	 pressure	 below	 treatment	 thresholds.	 Optimal	
treatment	 targets	 vary	 and	 are	 the	 subject	 of	 vigorous	 debate.17 
Treatment	 is	 typically	 lifelong	 with	 adjustment	 and,	 often,	 inten-
sification	 of	 antihypertensive	 treatment	 over	 time.	 Hypertension	
control	is	frequently	considered	suboptimal,	that	is	it	fails	to	reach	
specified	treatment	targets.18
Achieving	 blood	 pressure	 control	 has	 the	 potential	 for	 im-
proved	 outcomes	 and	 cost	 savings	 at	 the	 population	 level.19,20 
However,	 from	 an	 individual	 patient’s	 perspective,	 the	 potential	
benefits	are	less	certain.	Options	to	reduce	blood	pressure	include	
a	 choice	 of	 medications	 and	 lifestyle	 changes.	 Potential	 benefit	
will	 vary	with	 an	 individual’s	 overall	 cardiovascular	 risk,	 and	po-
tential	 disbenefits	 include	 medication	 side-	effects	 and	 the	 bur-
den	of	having	to	take	daily	medication.	Patients	making	decisions	
about	antihypertensive	drug	treatment	require	discussions	about	
treatment	 to	be	personalized	 in	order	 for	 the	decisions	 to	make	
sense	to	them.21	Shared	decision	making	for	hypertension	has	the	
potential	 to	 address	 this	 challenge,	 yet	 it	 is	 unclear	how	best	 to	
support	shared	decision	making	for	hypertension,	and	the	effect	
of	 shared	 decision	 making	 on	 outcomes	 is	 unknown.	 Given	 the	
high	prevalence	of	hypertension	and	its	impact	on	cardiovascular	
risk,	shared	decision	making	for	hypertension	may	have	profound	
impacts	at	both	individual	and	public	health	levels.
1.1 | Objective
The	main	 objective	 of	 this	 study	was	 to	 determine	 the	 effective-
ness	of	 interventions,	 including	but	not	 limited	to	decision	aids,	 to	
support	 shared	 decision	making	 in	 hypertension.	 A	 second	 objec-
tive	was	to	describe	the	outcomes	that	have	been	used	to	evaluate	
interventions	supporting	shared	decision	making	for	hypertension.
2  | METHODS
The	protocol	for	this	systematic	review	was	registered	on	PROSPERO	
(CRD42015014143).22
2.1 | Search strategy
We	used	 search	 strategies	 incorporating	 subject	heading	and	 text	
word	searches	focused	on	shared	decision	making	and	hypertension	
(see	Appendix	1	for	MEDLINE	searches).	The	search	was	developed	
in	MEDLINE	and	adapted	 for	subsequent	databases.	We	searched	
MEDLINE,	EMBASE,	CINAHL,	Web	of	Science,	PsycINFO	and	 the	
Cochrane	library	from	their	inception	to	September	2017.	We	iden-
tified	further	potentially	relevant	articles	from	forward	(via	Google	
Scholar)	and	backward	(reference	 list	of	paper)	citation	tracking	of	
included	studies,	applying	the	same	inclusion	criteria.
2.2 | Eligibility criteria
Following	 Cochrane	 Effective	 Practice	 and	 Organisation	 of	 Care	
(EPOC)	guidance,23	we	included	randomized	controlled	trials	(RCTs),	
nonrandomized	 controlled	 trials,	 controlled	 before-	after	 studies	
and	 interrupted	time	series	studies.	We	included	published	studies	
reporting	 on	 interventions	 supporting	 shared	 decision	 making	 for	
adults	 (>18)	 with	 hypertension.	 Eligible	 comparator	 interventions	
were	control	or	any	other	interventions.	Interventions	could	be	deliv-
ered	in	any	health-	care	setting,	either	before	or	during	consultations	
with	any	health-	care	professionals.	We	 included	studies	describing	
interventions	 that	 supported	 shared	 decision	 making	 by	 support-
ing	one	of	 the	 two	following	processes	of	shared	decision	making:	
supporting	 a	 patient’s	 consideration	 of	 their	 options	 in	 relation	 to	
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a	health-	care	choice;	or	 supporting	a	patient	 to	consider	 their	val-
ues	and	preferences	in	relation	to	a	health-	care	choice.	We	included	
studies	 in	which	 only	 a	 proportion	 of	 participants	were	 hyperten-
sive,	if	study	outcomes	were	reported	separately	for	the	hyperten-
sive	group.	We	excluded	studies	reporting	interventions	unrelated	to	
health-	care	decisions,	for	example,	purely	educational	interventions	
that	aimed	to	increase	hypertension	knowledge	without	reference	to	
health-	care	choices	faced	by	the	patient.	We	excluded	interventions	
that	aimed	to	increase	the	involvement	of	patients	in	their	own	care	
generally,	but	not	in	health-	care	decisions	specifically.	To	develop	an	
understanding	of	how	interventions	to	support	shared	decision	mak-
ing	were	evaluated,	we	included	studies	regardless	of	the	outcomes	
assessed.	No	date	or	language	restrictions	were	applied.
2.3 | Reference management and study selection
EndNote	X7.7	and	Access	2013	were	used	to	manage	the	references.	
Duplicates	were	removed	from	the	EndNote	file.	Titles	and	abstracts,	
and	subsequently	full	texts,	were	screened	independently	by	two	re-
viewers	(RJ,	BP	or	AH);	disagreements	were	resolved	by	discussion	
with	reference	to	a	third	reviewer	where	necessary	(KT,	GF	and	HC).	
If	there	was	insufficient	detail	on	potentially	relevant	studies	within	
the	report	abstract,	it	was	screened	as	full	text.	Reasons	for	exclu-
sions	of	full-	text	reports	were	documented.
We	scrutinized	the	text	and	reference	lists	of	relevant	systematic	
reviews	 for	 potentially	 eligible	 studies.	 Conference	 abstracts	 and	
relevant	 study	 protocols	were	 followed	up	 either	 by	 contact	with	
the	author	where	possible	or	by	searching	for	subsequent	publica-
tions	in	PubMed.
2.4 | Data extraction and risk of bias
Data	were	 extracted	 into	 a	 custom-	designed	 table	which	 had	 been	
previously	 piloted	 by	 one	 reviewer	 (RJ).	All	 data	were	 extracted	 by	
one	reviewer	and	checked	by	a	second.	Data	were	extracted	on	study	
type,	 setting,	 participants,	 interventions,	 controls,	 type	 of	 decision	
supported	and	outcome	measures.	Our	prespecified	primary	outcome	
was	any	measure	of	shared	decision	making.	Consistent	with	our	ob-
jective	of	documenting	what	outcomes	have	been	used	 to	evaluate	
interventions	 to	 support	 shared	 decision	making,	 all	 other	 reported	
outcomes	were	extracted	as	secondary	outcomes.	We	extracted	esti-
mated	effect	sizes	with	95%	confidence	intervals	for	each	outcome	as-
sessed,	using	odds	ratios	for	binary	variables	and	mean	differences	for	
continuous	variables.	Risk	of	bias	was	assessed	independently	by	two	
reviewers	using	the	Cochrane	EPOC	risk	of	bias	tool23;	disagreements	
were	resolved	by	discussion.	Risk	of	bias	in	some	domains	varied	with	
the	type	of	outcome	measure;	risk	of	bias	grouped	by	type	of	outcome	
is	presented	in	Figure	2.
2.5 | Data synthesis
For	 data	 pooling,	 where	 outcomes	 were	 assessed	 using	 different	
measures,	we	planned	 to	 calculate	 standardized	mean	differences	
(SMDs).	Meta-	analysis	was	planned	if	there	were	at	least	three	stud-
ies	with	comparable	interventions	and	outcomes	at	low	risk	of	bias.	
If	meta-	analysis	was	appropriate,	we	planned	to	assess	heterogene-
ity	amongst	studies	using	the	I2	statistic.	Analyses	were	carried	out	
using	Stata	version	14.1.24 
As	meta-	analysis	did	not	prove	possible,	we	present	a	narrative	
synthesis	of	the	studies.25	The	included	studies	are	summarized	in	
the	text,	in	a	table	of	study	characteristics	and	in	a	risk	of	bias	sum-
mary	table.	The	outcomes	reported	by	included	studies,	grouped	by	
type	of	 intervention,	are	reported	 in	Figure	3.	Outcomes	reported	
by	 at	 least	 three	of	 the	 included	 studies	 are	 compared	 across	 the	
studies	in	forest	plots	and	in	the	text.
3  | RESULTS
Searches	were	 run	 in	December	 2014	 and	 updated	 in	 September	
2017.	A	 total	 of	6424	unique	 articles	were	 screened,	 of	which	91	
full-	text	 articles	were	 assessed,	 and	 11	 reports	 of	 6	 studies	were	
included	in	the	review	(Figure	1).26-34
3.1 | Included studies
Eleven	papers	were	published	from	six	studies,	all	based	in	primary	
care	 (Table	1).	 Five	 studies	 reported	 randomized	 controlled	 tri-
als,26,27,29,30	of	which	two	were	cluster	randomized.29,30 The remain-
ing	study	was	a	nonrandomized	controlled	study.28
3.2 | Profile of patients
The	range	of	mean	age	of	study	participants	was	58.5-	64.5	years,	
and	the	range	of	female	participants	was	32.5%-	66.0%.	In	five	stud-
ies,	all	recruited	patients	had	hypertension.26-29,34	In	the	remaining	
study,30	 only	 a	 proportion	 of	 participants	 were	 hypertensive,	 al-
though	all	had	raised	cardiovascular	risk.	Only	results	relating	to	the	
hypertensive	patients	within	this	study	are	included	in	this	review.30
3.3 | Profile of interventions
The	interventions	were	heterogeneous	in	their	content	and	often	
multicomponent	 (Table	1).	 Intervention	 components	 included	
training	 interventions	 for	 clinicians,28,29,34	 coaching	 for	 patients,	
decision	 aids	 and	 written	 materials	 for	 patients.26,34	 Tinsel	 and	
colleagues29,32	 evaluated	 a	 shared	 decision-	making	 training	 pro-
gramme	 for	 general	 practitioners,	 to	 understand	 whether	 it	
increased	patients’	perceived	participation,	optimized	blood	pres-
sure	values,	enhanced	patient	knowledge	of	hypertension	and	im-
proved	adherence.	Deinzer	and	colleagues28,35	evaluated	a	shared	
decision-	making	 training	 intervention	 for	general	practitioners,28 
testing	the	hypothesis	that	shared	decision	making	would	lead	to	
more	effective	 lowering	of	hypertension.	 In	the	study	by	Cooper	
and	colleagues,34,36	a	communication	skill	training	intervention	for	
physicians	and	a	coaching	intervention	for	patients	were	evaluated,	
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separately	and	in	combination	with	each	other,	for	their	impact	on	
patient-	physician	communication	and	care	processes,	patient	ad-
herence	to	medication	and	lifestyle	recommendations,	and	blood	
pressure	 control.	 In	 two	 studies,	 the	 main	 intervention	 compo-
nent	was	a	decision	aid.27,30	 In	 the	 first	of	 these,	Denig	and	col-
leagues30,33	set	out	to	support	interactions	between	patients	and	
health-	care	providers	using	a	decision	aid	focusing	on	shared	goal	
setting	and	decision	making	for	patients	with	diabetes	considering	
their	 treatment	 options,	 including	 for	management	 of	 hyperten-
sion.	In	the	second	study,	Montgomery	and	colleagues27,31	set	out	
to	evaluate	the	effect	of	decision	analysis	as	an	aid	to	patient	deci-
sion	making	for	newly	diagnosed	hypertension	on	decision	quality,	
treatment	choices,	clinical	outcomes,	and	treatment	and	consult-
ing	behaviour.31	In	the	final	study,26	the	intervention	was	a	leaflet	
distributed	to	patients	with	hypertension	and	hypothesized	to	lead	
to	 greater	 involvement	 of	 patients	 in	 their	 health-	care	 choices,	
with	the	potential	for	improving	on	blood	pressure	control.
In	 four	studies,26,28,29,34	 interventions	supported	the	 involve-
ment	of	patients	with	established	hypertension,	without	specify-
ing	which	treatment	choices	were	being	supported.	In	one	study,27 
the	decision	supported	was	whether	to	commence	antihyperten-
sives	in	newly	diagnosed	hypertensive	patients.	The	intervention	
was	an	approximately	hour-	long	session	of	decision	analysis	which	
took	 place	 outside	 of	 the	 clinical	 encounter.	 One	 intervention	
aimed	to	support	shared	decision	making	 in	consultations	where	
multiple	treatment	options	to	lower	cardiovascular	risk	were	being	
considered,	 including	decisions	about	commencing	antihyperten-
sive	therapy.30
3.4 | Risk of bias
Risk	of	bias	assessment	is	reported	in	Figures	2	and	3.	One	nonrand-
omized	controlled	study	was	included	in	the	review	and	was	at	high	
risk	of	bias	for	most	domains.	Two	of	the	RCTs	were	at	uncertain	or	
high	risk	of	bias	for	the	majority	of	domains.26,34	Three	RCTs	were	at	
low	risk	for	most	domains.27,29,30	However,	the	two	RCTs	reporting	
shared	decision	making	were	at	uncertain	 risk	of	bias	 for	 this	out-
come	because	of	the	impossibility	of	blinding	for,	as	well	as	the	sub-
jectivity	of,	this	outcome.
3.5 | Outcomes
The	 included	 studies	 assessed	 a	 range	 of	 outcome	 measures.	
Outcomes	 reported,	 by	 intervention	 type	 and	 risk	 of	 bias,	 are	
shown	 in	 Figure	3.	 Four	 studies	 reported	 a	measure	 of	 shared	
decision	 making.27,28,32,34	 Clinical	 outcomes	 reported	 were	
as	 follows:	 blood	 pressure	 (five	 studies),26,28,29,31,34	 hyper-
tension	 treatment	 (two	 studies),30,31	 cardiovascular	 risk	 (two	
F IGURE  1 PRISMA	flow	diagram
7813
Records identified through 
database searching
noitacifitnedI
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ili
ty
80
Full-text articles excluded, 
with reasons:
Not shared decision 
making (35)
Not controlled study (11)
Not hypertensives (2)
Hypertensives not 
separated out (10)
No relevant outcomes
reported (22)
6333
Records excluded 
1403
Duplicates removed
14
Records identified through 
author contact and reference 
lists
11 reports of 6 studies
included in synthesis
91
Full-text articles assessed for 
eligibility
6424
Records after duplicates 
removed that were screened 
by title and abstract 
7827
Screened for duplicates
     |  1195JOHNSON et al.
TABLE  1 Characteristics	of	included	studies
Study, year, country 
Design 
N = randomized 
Setting/recruitment
Baseline characteristics of 
participants:
Intervention(s) 
n = number randomized
Control 
n = number randomized
Watkins	1987	United	
Kingdom
RCT
N	=	565
Primary	care
Patients	dispensed	
antihypertensives	by	
pharmacy
OR
Patients	on	GP	hyperten-
sion	disease	register
Only	whole	sample	data	
reported
Age:	“almost	2/3	were	55-	64”
%	female:	59%
Ethnicity:	27%	non-	Caucasian
Hypertension	status:
“very	similar	with	respect	to	
diastolic	blood	pressure	prior	
to	the	start	of	the	study”
Of	75%	(313)	having	BP	
recorded	in	6	mo	prior	to	the	
study,	147	(47%)	had	DBP	of	
at	least	95	mmHg
n	=	204	participants	analysed;	numbers	
randomized	not	reported	by	intervention	
group
Information	and	medical	record	booklet:
Mailed	booklet	with	information	on	
hypertension	including	treatment	options,	
with	the	aim	of	providing	an	opportunity	for	
the	general	practitioner	and	patient	to	set	
the	objectives	of	management	together	and	
to	share	information	on	how	well	these	had	
been	obtained.
n	=	210	participants	analysed;	
numbers	randomized	not	
reported	by	intervention	group
control	intervention	not	further	
specified
Montgomery	2003
Emmett	2005	(3-	y	
follow-	up)
United	Kingdom
2	×	2	factorial	RCT	(patients	
randomized)
4	groups*:	1.	Decision	
analysis;	2.	Decision	
analysis	+	video/leaflet;	3.	
Video/leaflet;	4.	Usual	care
N	=	217
Primary	care
Age	30-	80	not	currently	
taking	antihypertensives,	
BP	sustained	at	a	level	
where	GP	would	normally	
discuss	initiation	of	
pharmacological	therapy.
Age	(SD):
Intervention:
Decision	analysis	alone	59	(9),
Decision	analysis	+	video/
leaflet	57	(11)
Control:
Usual	care	58	(11),	Video/
leaflet	60	(10)
%	female:
Intervention:
Decision	analysis	alone	46%
Decision	analysis	+	video/
leaflet	49%
Control:	Usual	care	49%,	
Video/leaflet	47%
Ethnicity:	not	reported
Hypertension	status:	Mean	
SBP/DBP	in	mmHg	(SD)
Intervention:
Decision	analysis	alone	167	
(11)/99	(6)
Decision	analysis	+	video/
leaflet	170	(14)/98	(8)
Control:
Usual	care	169	(13)/100	(9)
Video/leaflet	166	(14)/97	(8)
n	=	103,	of	which:
52	received	decision	analysis	alone,	51	
received	decision	analysis	+	video/leaflet
Decision	analysis	session	(1	h	with	
researcher),	in	which	patient	participant’s	
values	regarding	treatment	outcomes	are	
combined	with	individual	cardiovascular	
risk	information	to	create	a	decision	tree	to	
support	decision	making.	Results	of	the	
decision	analysis	are	presented	as	a	paper	
summary
Video/leaflet:	Factual	information	including	
about	BP,	self-	help	measures	and	BP	
medication
n	=	114,	of	which:
55	received	video/leaflet	in	
addition	to	usual	care,	and	59	
received	usual	care
Usual	care—not	further	
specified
Video/leaflet:
Factual	information	including	
about	BP,	self-	help	measures	
and	BP	medication
Deinzer 2009
Deinzer 2006
Germany
Nonrandomized	controlled
N	=	86
Primary	care
Patients:
BP>/=	135/85	mmHg,	
excluding	those	with	
severe	hypertension	(BP	
>/=	160/100	mmHg),	poor	
control,	established	
cardiovascular	disease	or	
diabetes	mellitus
GPs	(not	characterized)
Intervention,	control
Age (SD):
60.9	(10.1),	61.1(9.3)
Female	(%):
67.5%,	65%
Ethnicity:
Not	specified
Hypertension	status:
Mean	systolic	blood	pressure	
mmHg	(SD):
145.4	(11.7),	144.9	(11.1)
Mean	diastolic	blood	pressure	
mmHg	(SD):
86.6	(8.2),	86.1	(9.1)
n	=	40
Training	programme	for	GPs	“to	develop	
communication	skills	necessary	to	practice	
shared	decision	making”
Regular	supervision	of	trained	physicians
Regular	consultations	between	trained	
physicians	and	patients	to	make	decisions	
on	further	treatment	(at	1,	3,	6	and	12	mo)
Hypertension	education	module	for	
patients
n	=	46
Hypertension	education	module	
for	patients
(Continues)
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Study, year, country 
Design 
N = randomized 
Setting/recruitment
Baseline characteristics of 
participants:
Intervention(s) 
n = number randomized
Control 
n = number randomized
Cooper	2011
Cooper	2009	(protocol	
paper)
USA
2	×	2	factorial	RCT
N	=	279	patients
N	=	50	physicians
4	groups:	1.	Physician	
intensive	intervention/
patient	intensive	
intervention;	2.	Physician	
minimal	intervention/
patient	intensive	
intervention;	3.	Physician	
intensive	intervention/
patient	minimal	interven-
tion;	4.	Physician	and	
patient	minimal	interven-
tion	(serves	as	reference	
group	for	comparisons)
Patients:
Adults	(18+	y)	with	
hypertension
Physicians:
General	internists/family	
physicians	seeing	patients	
in	community-	based	
primary	care	sites
Patient	participants
Physician	intensive/patient	
intensive:
Age	(SD):	59.7	(11.9)
Female	(%):	65.1
Ethnicity	(%):
African	American	62.6%
Asian	2.4%
American	Indian	0%
White	34.9%
REALM	>/=	9th	Grade:	59.8%
Physician	minimal/patient	
minimal
Age	(SD):	62.4	(12.1)
Female	(%):	61.8
Ethnicity	(%):
African	American	58.2%
Asian	0%
American	Indian	1.8%
White	40%
REALM	>/=	9th	Grade:	70.9%
n	(patients)	=	224
Intervention	groups:
Physician	intensive/patient	intensive,	n	=	83
Physician	minimal/patient	intensive,	n	=	57
Physician	intensive/patient	minimal,	n	=	84
Patient	intensive	intervention:
Previsit	coaching,	by	community	health	
workers	(CHWs)	to	support	patient	
participation.	CHWs	supported	patients	to	
identify	changes	they	wanted	to	make	to	
their	interactions	with	their	physicians,	
including	practising	asking	questions	and	
stating	preferences.
Stage	1:	20-	min	previsit	coaching	session	
prior	to	index	visit	with	physician;	10-	min	
debriefing	after	the	visit.
Stage	2:	(i)	5	×	10-	15-	min	phone	calls	over	
12	mo;	telephone	support	between	these	
times
(ii)	Bimonthly	photonovel	depicting	patients	
and	physicians	dealing	with	daily	
challenges	of	hypertension	management
(iii)	Monthly	newsletter	including	informa-
tion	about	living	with	hypertension
Physician	intensive	intervention:
Communication	skill	training	programme:
Videotaped	consultation	between	physician	
and	simulated	patient	(African	American	
hypertensive	man)	prior	to	the	study	
randomization.	Physician	receives	
CD-	ROM	on	which	the	videotaped	
consultation	is	recorded	and	coded	(using	
Roter	interaction	analysis	system),	with	
individualized	feedback	on	communication	
skills	relevant	to	increasing	patient	
engagement,	activation,	empowerment	
and	adherence.	Five	specific	behaviours	
targeted:	1.	Elicit	full	spectrum	of	the	
patient	concerns;	2.	Probe	pts	hyperten-
sion	knowledge	and	beliefs;	3.	Monitor	
adherence	and	identify	barriers;	4.	Assess	
adherence-	related	lifestyle	and	psychoso-
cial	issues;	5.	Elicit	commitment	to	the	
therapeutic	plan
An	accompanying	workbook	includes	
exercises	for	the	physician	to	complete.	
Estimated	time	to	complete	workbook:	
2 h
Physicians	receive	a	copy	of	the	JNC-	VII	
hypertension	treatment	guidelines	
at	baseline	and	a	monthly	newsletter	
with	study	updates/recent	evidence	
updates
n	(patients)	=	55
The	“Physician	minimal/patient	
minimal”	serves	as	reference	
group	with	which	changes	in	
outcome	are	compared:
Patient	minimal	intervention:
Monthly	newsletter	including	
information	about	living	with	
hypertension
Physician	minimal	intervention:
Videotaped	consultation	with	a	
simulated	patient	(African	
American	hypertensive	man)	
prior	to	the	study	randomiza-
tion;	no	feedback	on	the	
consultation	is	received
Physicians	receive	a	copy	of	the	
Joint	National	Committee	7th	
report	hypertension	treatment	
guidelines	at	baseline	and	a	
monthly	newsletter	with	study	
updates/recent	evidence	
updates
TABLE  1  (Continued)
(Continues)
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Study, year, country 
Design 
N = randomized 
Setting/recruitment
Baseline characteristics of 
participants:
Intervention(s) 
n = number randomized
Control 
n = number randomized
Tinsel	2013	Germany
Tinsel	2012	(protocol	paper)
Germany
Cluster	RCT	(randomization	
at	practice	level)
Primary	care
N	(GP	practices)	=	36
N	(patients)	=	1120
Practices:
Located	in	south-west	
Germany;	offering	the	full	
spectrum	of	family	
doctor’s	health-	care	
services;	not	participating	
in	another	study	of	shared	
decision-	making	
implementation
Patients:
Prescribed	regular	
antihypertensive	
medications,	who	either 
have	poorly	controlled	BP	
(24	h	mean	>130/80)	or 
controlled	BP	with	
cardiovascular	comorbidity
Intervention,	control
Age	(SD):
63.8	(12.1),	65.0	(±	12.4)
Female	(%):
53.3%,	55.3%
Ethnicity:
Not	reported
Hypertension	status:
Mean	SBP	in	mmHg	(SD)
128.9	(12.5),	127.0	(11.8)
Mean	DBP	in	mmHg	(SD)
79.2	(9.5),	76.8	(9.1)
17	GP	practices
n	(patients)	=	552
Training	programme	for	GPs.	Training	was	
delivered	over	two	or	three	sessions	of	3	h	
each	and	included	education	about	
hypertension,	principles	of	risk	communi-
cation,	implementation	of	shared	decision	
making,	use	of	motivational	interviewing,	
the	use	of	a	decision	aid	listing	options	to	
lower	cardiovascular	risk	and	role-	playing	
of	case	vignettes
Cardiovascular	risk	table	“including	
elements	of	shared	decision	making”
Patient	information	flyers	for	GPs	to	
distribute
Six-	monthly	ambulatory	blood	pressure	
measurements	and	GP	consultation	at	
which	blood	pressure	management	was	
discussed	and	outcomes	measured
19	GP	practices
n	(patients)	=	568
Usual	care
Six-	monthly	ambulatory	blood	
pressure	measurements	and	
GP	consultation	at	which	blood	
pressure	management	was	
discussed	and	outcomes	
measured
Denig	2014
Denig	2012	(protocol	paper)
The	Netherlands
Cluster	RCT	with	2	×	2	
factorial	design	with	a	
control	group	(randomiza-
tion	at	practice	level	
(computer	version	or	
printed	version),	and	
subsequently	at	patient	
level	[short	version,	
extended	version,	or	
control])
General	practice
N	(practices)	=	18
N	(patients)	=	344
Practices:
General	practices	in	the	
north	Netherlands
Patients:
Patients	with	diabetes	
under	age	65	when	
diagnosed,	excluding	those	
with	recent	cardiovascular	
events
Considered	eligible	for	BP	
treatment	intervention	
when	SBP>=	140
Intervention,	control
Age	(SD):
61.8	(8.5),	61.5	(8.5)
Female	(%):
42%,	26%
Ethnicity:
not	reported
Low	educational	attainment:
40%,	38%
Hypertension	status:
Uncontrolled	SBP	
>=140	mmHg	(%)
50%,	42%
n	(patients)	=	225
Prior	to	the	study,	health-	care	professional	
received	training	course	in	motivational	
interviewing	and	risk	communication
Decision	aid	for	use	before	consultation	
(patient)	and	during	consultation	(with	
health-	care	professional)	including	tailored	
information	on	risks	and	treatment	options	
for	multiple	risk	factors	(Hba1c,	SBP,	LDL	
and	smoking),	focusing	on	shared	goal	
setting	and	decision	making
Two	forms	of	the	decision	aid	were	assessed	
using	the	factorial	design:	SHORT	version	
presenting	risk	of	myocardial	infarction	
only,	or	EXTENDED	version	presenting	
additional	outcomes
n	(patients)	=	119
Usual	care
Components	of	intervention:	
Prior	to	the	study,	health-	care	
professionals	received	training	
course	in	motivational	
interviewing	and	risk	
communication
BP,	blood	pressure;	CHW,	community	health	worker;	DA,	decision	analysis;	DBP,	diastolic	blood	pressure;	GP,	general	practitioner;	Hba1c,	glycated	
haemoglobin;	JNC-	VII,	The	Seventh	Report	of	the	Joint	National	Committee;	LDL,	low-	density	lipoprotein;	RCT,	randomized	controlled	trial;	REALM,	
rapid	estimate	of	adult	literacy	in	medicine;	SBP,	systolic	blood	pressure;	SD,	standard	deviation.
TABLE  1  (Continued)
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F IGURE  2 Risk	of	bias	of	primary	studies.	Effective	Practice	and	Organisation	of	Care	(EPOC)	risk	of	bias	assessment	of	included	studies,	
by	outcome	grouping,	for	outcomes	reported	in	at	least	three	studies	(Except	Denig,	where	risk	of	bias	is	reported	for	the	single	outcome	
extracted	for	this	review).	BP,	blood	pressure;	DCS,	Decisional	Conflict	Scale;	API,	Autonomy	Preference	Index;	SDM,	shared	decision	
making;	SDM-	Q-	9,	9-	item	Shared	Decision	Making	Questionnaire
W
as
 th
e 
al
lo
ca
tio
n 
se
qu
en
ce
 a
de
qu
at
el
y 
ge
ne
ra
te
d?
W
as
 th
e 
al
lo
ca
tio
n 
ad
eq
ua
te
ly
 c
on
ce
al
ed
?
W
er
e 
ba
se
lin
e 
ou
tc
om
e 
m
ea
su
re
m
en
ts
 
sim
ila
r?
W
er
e 
ba
se
lin
e 
ch
ar
ac
te
ris
tic
s s
im
ila
r?
W
er
e 
in
co
m
pl
et
e 
ou
tc
om
e 
da
ta
 a
de
qu
at
el
y 
ad
dr
es
se
d?
W
as
 k
no
w
le
dg
e 
of
al
lo
ca
te
d
in
te
rv
en
tio
n
ad
eq
ua
te
ly
 p
re
ve
nt
ed
 d
ur
in
g 
th
e 
st
ud
y?
W
as
 th
e 
st
ud
y 
ad
eq
ua
te
ly
 p
ro
te
ct
ed
 a
ga
in
st
 
co
nt
am
in
at
io
n?
W
as
 th
e 
st
ud
y 
fr
ee
 fr
om
 se
le
ct
iv
e 
ou
tc
om
e 
re
po
rt
in
g?
W
as
 th
e 
st
ud
y 
fr
ee
 fr
om
 o
th
er
 ri
sk
s o
f b
ia
s?
O
ve
ra
ll 
as
se
ss
m
en
t
Watkins 
i. BP (primary outcome) 
ii. Hypertension knowledge
U U U U U H H L L H
Montgomery, Emmett
i. DCS (primary outcome)
ii. Adherence
L L L L L H L L L U
iii. BP
iv. Hypertension knowledge
L L L L L L L L L L
Deinzer (primary outcome not specified)
i. BP
ii. Hypertension knowledge
H H H H L U U L U H
iii. API 
iv. COMRADE
H H H H L H U L U H
Cooper
i. Appointment keeping 
(primary outcome)
L L U L H U H H U H
ii. SDM/adherence L L U L H H H H U H
iii. BP L L U L H L L H U H
Tinsel
i. SDM Q-9 (co-primary 
endpoint)
ii. Adherence
L L L L L H L L L U
iii. BP (co-primary endpoint) L L L L L L L L L L
iv. Hypertension knowledge L L L L L L L L L L
Denig
i. Intensification of 
treatment
L L L L L L H L L U
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studies),31	 diagnosis	 of	 diabetes,	 left	 ventricular	 hypertrophy	
and	 lipid	 profile	 (all	 reported	 in	 a	 single	 study).31	 Behavioural	
utcomes	 were	 medication	 adherence	 (three	 studies),29,31,34 
smoking	 status	 (one	 study)31	 and	 intention	 to	 start	 treatment	
(one	 study).31	 Anxiety	 was	 the	 only	 psychological	 outcome	
reported	 (one	 study).27	 Cognitive	 outcomes	 were	 hyperten-
sion	 knowledge	 (four	 studies)26-29	 and	 intention	 to	 start	 treat-
ment	 (one	 study).27	 Only	 one	 study	 reported	 a	 measure	 of	
health-	care	 use.30	 Other	 outcomes	 included	 health-	related	
quality	 of	 life	 (one	 study)28	 and	 clinician	 communication	 
(one	study).33
Here,	we	discuss	our	primary	outcome	(shared	decision	making),	
and	the	outcomes	reported	in	at	least	three	of	the	included	studies	
(blood	 pressure,	 hypertension	 knowledge	 and	 medication	 adher-
ence).	 The	 decision	 to	 limit	 our	 discussion	 to	 the	most	 commonly	
reported	one	was	a	post	hoc	decision,	as	detailed	reporting	of	all	of	
the	outcomes	reported	was	not	practical.	All	outcomes	are	reported	
in	Table	2.	None	of	the	outcomes	met	our	prespecified	criteria	for	
meta-	analysis	 of	 at	 least	 three	 studies	with	 comparable	 interven-
tions	and	outcomes	at	 low	risk	of	bias;	 therefore,	we	did	not	pool	
data	for	any	outcome.
3.5.1 | Primary outcome: shared decision making—
risk of bias (Figure 2) and results (Table 2 and Figure 4)
The	four	studies	measuring	shared	decision	making27-29	used	differ-
ent	patient	self-	report	measures;	measures	are	described	in	Table	2.	
Shared	 decision	 making	 was	 assessed	 at	 different	 times,	 ranging	
from	14	days	to	18	months	after	the	intervention.	In	studies	in	which	
patients	received	an	intervention,	blinding	patients	to	treatment	al-
location	 was	 not	 possible.	 All	 studies	 measuring	 shared	 decision	
making	 in	 this	 review	were	 assessed	 as	 uncertain27-29	 or	 high	 risk	
of	bias28,34	for	this	outcome,	due	to	inadequate	prevention	of	treat-
ment	allocation	knowledge.	The	SMD	 in	 change	 from	baseline	 for	
shared	decision-	making	measures,	for	studies	with	useable	data	at	
12	months,	is	shown	in	Figure	3.
Tinsel	 and	 colleagues29	 use	 the	 nine-	item	 Shared	 Decision	
Making	Questionnaire	(SDM-	Q-	9)37	as	a	coprimary	outcome	for	the	
study.	The	mean	SDM-	Q-	9	score	decreased	in	both	intervention	and	
control	 groups.	The	difference,	 between	 intervention	and	 control,	
in	 mean	 change	 from	 baseline	 (to	 approximately	 18	months)	 was	
3.1182,	97.5%	CI	−2.3730;	8.6093,	P	=	0.2029.
Deinzer28	 reported	 two	 shared	 decision-	making	measures:	 the	
Autonomy	Preference	 Index	 (API)38	 and	a	modified	version	of	 the	
COMRADE	scale.39	In	this	study	with	a	high	risk	of	bias,	the	authors	
report	 that	 at	1	year	 there	was	no	change	 in	API	 from	baseline	 in	
either	the	intervention	or	control	group,	although	API	scores	were	
not	reported	(P	=	0.83	for	the	comparison).	A	comparison	between	
the	COMRADE	scores	 in	 the	 intervention	and	control	groups	was	
not	reported.
The	 primary	 outcome	 in	 the	 study	 by	 Montgomery	 and	 col-
leagues27	was	the	Decisional	Conflict	Scale	(DCS),	a	16-	item	patient	
self-	report	scale.40	The	DCS	was	measured	after	receipt	of	the	inter-
vention	(mean	14	days	after	randomization).	The	adjusted	difference	
in	mean	DCS	score	(decision	analysis	vs	no	decision	analysis)	was	−9.4	
(95%	CI	−13.0	to	−5.8),	P < 0.001.
F IGURE  3 Outcomes	reported	in	included	studies,	by	intervention	type	and	risk	of	bias.	RED	=	high	risk	of	bias;	ORANGE	=	uncertain	
risk	of	bias;	GREEN	=	low	risk	of	bias;	HCP	=	health-	care	professional.	*Outcomes	reported	for	the	study	by	Denig	are	only	those	reported	
for	the	hypertensive	subgroup	within	the	study
Intervention 
type
Study Outcomes assessed
Communication 
outcomes
Clinical outcomes Behavioural outcomes Cognitive outcomes Healthcare 
use
Other
Patient reported 
Shared 
decision 
making 
Clinician 
communi 
cation
Blood Cardiovascular 
risk
Treatment 
intensification 
/chanage
Adherence Smoking 
status
Hypertension 
knowledge
Treatment intention Anxiety HRQOL
pressure
HCP training Deinzer
Tinsel
HCP training 
/patient 
coaching
Cooper
Decision aid Montgomery
Denig*
Patient 
leaflet
Watkins
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Cooper	 and	 colleagues	 report	 two	measures	 of	 shared	 deci-
sion	making.	The	first	measure	is	the	patient-reported	Physicians’	
Participatory	 Decision-Making	 Style	 (PDM),41	 and	 the	 second	
measure	 is	 the	 Patients’	 Perceived	 Involvement	 in	 Care	 Scale	
(PICS),42	a	measure	with	three	subscales:	doctor	facilitation	of	pa-
tient	involvement;	information	exchange;	and	patient	participation	
in	medical	decision	making.	There	were	three	intervention	groups,	
physician	and	patient	 intensive,	physician	minimal/patient	 inten-
sive	 and	 physician	 intensive/patient	minimal,	 and	 one	 reference	
group,	physician	and	patient	minimal.	For	each	scale	and	interven-
tion	group,	the	study	reported	change	from	baseline	at	12	months	
and a P-	value	 from	 the	 comparison	 with	 the	 reference	 group.	
For	all	 intervention	groups,	there	was	no	statistical	evidence	of	a	
change	in	PDM	at	12	months.	Mean	PDM	decreased	from	baseline	
in	the	reference	group	−5.2	 (95%	confidence	 interval	−13.0,	2.5)	
but	increased	from	baseline	in	the	other	intervention	groups:	phy-
sician	intensive/patient	intensive	group:	6.2	(−0.5,	12.9);	physician	
minimal/patient	 intensive	 group:	 3.2	 (−4.8,	 11.3);	 and	 physician	
intensive/patient	minimal:	3.1	 (−3.9,	10.2).	P	values	for	the	com-
parison	of	the	change	in	PDM	at	1	year	between	each	intervention	
group	and	 the	 reference	group	were	 as	 follows:	physician	 inten-
sive/patient	 intensive	 group	 P	=	0.03;	 physician	 minimal/patient	
intensive	group	P	=	0.13;	and	physician	intensive/patient	minimal	
P	=	0.12.	Taken	together,	 it	 is	uncertain	whether	the	intervention	
led	 to	 a	 change	 in	 PDM.	 Similar	 patterns	were	 reported	 for	 the	
three	PICS	subscales.	Taken	together,	 it	 is	uncertain	whether	the	
intervention	led	to	a	change	in	PDM.
3.5.2 | Secondary outcomes—risk of bias 
(Figure 2) and results (Table 2 and Figures 5 and 6)
Five	studies	evaluated	the	effect	of	the	intervention	on	blood	pres-
sure26,28,29,31	 (Table	2);	 two	 studies	 were	 at	 low	 risk	 of	 bias,	 and	
three	were	at	high	risk	of	bias,	for	this	outcome26,28	(Figure	2).	Blood	
pressure	was	measured	at	different	time	points	(range	6	months	to	
3	years).	Four	of	the	five	studies	(two	at	low	risk	of	bias)	report	that	
there	was	no	difference	between	blood	pressure	in	the	intervention	
and	control	groups;	in	the	fifth	study,	intervention	and	control	were	
not	formally	compared.	The	mean	difference	in	change	from	baseline	
after	1	year	in	three	studies	with	useable	data	is	shown	in	Figure	5.
Hypertension	knowledge	was	assessed	in	four	studies,26,28,29,31 
at	 different	 time	 points	 (range	 14	days	 to	 18	months),	 using	 dif-
ferent	scales	in	each	study.	Results	were	conflicting:	two	studies	
reported	 that	 the	 intervention	 increased	 hypertension	 knowl-
edge,26,27	and	two	studies28,29	reported	that	there	was	no	statisti-
cal	evidence	of	a	difference	in	hypertension	knowledge	between	
intervention	and	control.	Two	studies	reported	comparable	scales	
at	 similar	 time	 points;	 SMDs	 for	 these	 studies	 are	 reported	 in	
Figure	6.
Adherence	 was	 assessed	 in	 three	 studies27,29,34	 at	 different	
time	points	(range	6	months	to	3	years)	and	using	different	patient	
self-	report	measures;	two	studies29,31,34	were	at	uncertain	risk,	and	
one	study43	was	at	high	risk	for	this	outcome.	In	each	of	the	three	
studies,	 there	was	no	statistical	evidence	of	a	difference	between	
intervention	and	control	 in	patient-	reported	adherence.	Reporting	
F IGURE  4 Change	in	shared	decision	making	at	1	y.	Forest	plot	of	the	standardized	mean	difference	(SMD)	of	change	from	baseline	for	
shared	decision-	making	scales:	SDM-	Q-	9,	Physicians’	Participatory	Decision-	Making	Style	(PDM)	and	subscales	of	the	Patients’	Perceived	
Involvement	in	Care	Scale	(PICS)	[doctor	facilitation,	information	exchange	and	decision	making].	Tinsel:	results	adjusted	for	baseline	values	
of	outcomes.	Cooper:	no	adjustment	reported
F IGURE  5 Change	in	systolic	blood	pressure	at	1	y.	Forest	plot	
of	the	mean	difference	in	change	from	baseline	of	systolic	blood	
pressure	(mmHg),	between	intervention	and	control.	Tinsel:	results	
adjusted	for	baseline	values	of	outcomes.	Cooper:	no	adjustment	
reported.	Deinzer:	no	adjustment	reported
F IGURE  6 Change	in	hypertension	knowledge	at	1	y.	Forest	plot	
of	the	standardized	mean	difference	(SMD)	of	change	from	baseline	
for	hypertension	knowledge.	Tinsel:	results	adjusted	for	baseline	
values	of	outcomes.	Cooper:	no	adjustment	reported
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of	adherence	was	not	comparable	between	the	studies,	and	SMDs	
were	not	calculated	for	this	outcome.
4  | DISCUSSION
This	review	identified	a	small	number	of	studies	evaluating	the	effec-
tiveness	of	different	interventions	to	support	shared	decision	making	
in	 the	management	 of	 hypertension.	Meta-	analysis	 of	 the	 included	
studies	was	not	undertaken	because	of	clinical	heterogeneity	(differ-
ences	 in	 interventions	and	outcomes)	and	methodological	heteroge-
neity	 (differences	 in	the	risk	of	bias	of	studies).	We	have	found	that	
there	is	insufficient	evidence	to	inform	which	intervention	should	be	
used	 to	support	 shared	decision	making	 for	hypertension	 in	 routine	
clinical care.
We	 identified	 six	 studies	 (five	 randomized	 controlled	 tri-
als26,27,29,30,43	 and	 one	 controlled	 study)26	 evaluating	 interventions	
to	 support	 shared	 decision	 making	 for	 hypertension.	 The	 main	 in-
tervention	 components	 were	 training	 for	 health-	care	 professionals	
(three	 studies),28,29,34	 decision	 aids	 (two	 studies),27	 patient	 coaching	
(one	study)34	and	a	patient	 leaflet	 (one	study).26	All	 included	studies	
were	 based	 in	 primary	 care.	 No	 studies	 measuring	 shared	 decision	
making	were	at	 low	risk	of	bias	for	this	outcome.	Two	trials,	both	at	
uncertain	risk	of	bias,	had	conflicting	results:	in	one,	a	GP	training	in-
tervention	did	not	increase	patient-	perceived	shared	decision	making	
over	18	months,29	and	in	the	second	study,	decision	analysis	reduced	
decisional	conflict	at	14	days.27	Of	two	further	studies	at	high	risk	of	
bias,34	only	one	provided	useable	data28;	in	this	study,	it	was	uncertain	
whether	an	intensive	intervention	(clinician	training	and	patient	coach-
ing)	improved	patient-	reported	perceptions	of	clinicians’	participatory	
decision-	making	style	(PDM)	or	involvement	in	care	(PICS).	Four	stud-
ies	compared	blood	pressure	between	 intervention	and	control26-29; 
they	reported	no	statistically	significant	difference	in	blood	pressure	
at	time	points	between	3	months	and	3	years.
Of	 the	 interventions	 in	 the	primary	 studies,	 only	one	 addressed	
shared	decision	making	about	whether	or	not	to	initiate	an	antihyper-
tensive	medication,	which	is	a	key	decision	point	in	the	management	
of	 hypertension.	 The	 intervention	 was	 an	 approximately	 hour-	long	
session	of	decision	analysis	which	 took	place	outside	of	 the	 clinical	
encounter.	This	was	the	only	study	reporting	 increased	shared	deci-
sion	making	in	the	intervention	group	in	comparison	with	controls,	al-
though	the	impossibility	of	blinding	participants	and	the	self-	reported	
nature	of	the	outcome	measure	rendered	the	study	at	uncertain	risk	of	
bias.	The	intensity	of	the	intervention	in	this	study	makes	it	unlikely	to	
be	feasible	in	routine	health-	care	settings.
Strengths	of	this	review	include	the	use	of	a	comprehensive	search	
strategy	employing	a	range	of	synonyms	for	shared	decision	making.	
Our	definition	of	shared	decision	making	builds	on	previous	research	
in	this	area;	our	two	core	components	of	shared	decision	making	were	
the	elements	that	appear	most	frequently	in	conceptual	definitions	of	
shared	decision	making44	and	are	central	to	the	most	frequently	cited	
model	of	decision	making.45	To	avoid	missing	eligible	studies,	we	were	
inclusive	at	the	title	and	abstract	screening	stage,	where	intervention	
descriptions	were	often	sparse.	No	 language	restrictions	were	used,	
and	 screening	was	 carried	 out	 in	 duplicate.	 Uncertainties	 about	 in-
clusion	were	discussed	within	a	multidisciplinary	team	of	GPs/health	
service	researchers	and	social	scientists	to	ensure	validity	of	selection.	
Using	a	narrative	synthesis	approach,	we	have	been	able	to	apply	tools	
systematically	 resulting	 in	 a	 robust	 summary	 of	 the	 available	 stud-
ies,	as	well	as	highlighting	where	the	evidence	base	is	limited.	To	our	
knowledge,	 this	 is	 the	first	study	to	review	 interventions	to	support	
shared	decision	making	for	hypertension.
Limitations	of	this	review	include	the	small	number	of	eligible	stud-
ies,	many	of	which	were	at	uncertain	or	high	risk	of	bias.	The	included	
studies	described	a	 range	of	 interventions	and	evaluated	a	 range	of	
outcome	measures,	making	it	more	challenging	to	summarize	the	data	
using	a	narrative	approach.	Although	useful	in	providing	an	overview	
of	 the	 evidence	 available	 (Figure	 3),	 this	 clinical	 heterogeneity	 pre-
vented	pooling	of	 the	data.	An	 important	 limitation	of	 the	 included	
studies	is	that	measurement	of	shared	decision-	making	outcomes	was	
biased	by	 the	 lack	of	blinding	of	outcome	assessment	 and	 the	 sub-
jective	nature	of	shared	decision-	making	outcomes.	The	mechanisms	
by	which	interventions	might	achieve	their	outcomes	were	not	clearly	
articulated	within	the	papers.	The	rationale	implied	in	several	studies	
is	that	shared	decision	making	might	enhance	patient’s	understanding	
and	 through	 this	 compliance	with	antihypertensive	medication.	This	
rationale	is	evident	in	the	choice	of	hypertension	knowledge	and	ad-
herence	as	study	outcomes.	Explicit	acknowledgement	of	the	mech-
anisms	 by	which	 interventions	 are	 expected	 to	 influence	 outcomes	
including	shared	decision	making,	for	example	through	a	logic	model,	
would	be	helpful	in	interpreting	study	findings.
Research	in	conditions	other	than	hypertension	has	suggested	that	
shared	decision	making	has	the	potential	 to	 improve	outcomes,10 in-
crease	 appropriateness	 of	 care,8	 reduce	 overtreatment9 and reduce 
treatment	costs.11	Given	 the	 limitations	of	 the	studies	within	 the	 re-
view,	 the	 effects	 of	 shared	 decision	making	 in	 hypertension	 remain	
uncertain,	and	none	of	these	potential	benefits	can	be	confirmed.	The	
interventions	in	several	of	the	included	studies28-30,33	aimed	to	change	
the	behaviour	of	clinicians	 in	order	to	facilitate	shared	decision	mak-
ing.	The	 challenges,	 for	 health	 professionals,	 in	 implementing	 shared	
decision	making	have	been	well	described	and	include	time	constraints	
and	the	perceived	lack	of	applicability	of	shared	decision	making	to	the	
particular	clinical	situation.7	A	recent	review	focussing	on	studies	mea-
suring	shared	decision	making	and	patient	outcomes	found	that	shared	
decision	making,	when	perceived	to	be	happening	by	patients,	tended	
to	result	in	improved	affective-	cognitive	outcomes,	but	that	evidence	
was	lacking	for	patient	behavioural	and	health	outcomes.46	Consistent	
with	this	review,	we	found	that	all	of	our	 included	studies	that	mea-
sured	shared	decision	making	used	a	patient-	reported	measure.
In	the	care	of	people	with	hypertension,	there	 is	a	potential	con-
flict	between	the	aim	of	ensuring	shared	decision	making	occurs,	and	
the	aim	of	optimizing	blood	pressure	control.	Several	of	the	 included	
studies	aimed	to	do	both.	The	effect	of	shared	decision	making	on	clin-
ical	outcomes	is	important	because,	should	it	be	implemented	widely,	
it	has	the	potential	to	impact	on	public	health	outcomes.47	For	exam-
ple,	should	the	consequence	of	shared	decision	making	be	that	fewer	
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people	take	antihypertensive	medication,	this	will	 increase	cardiovas-
cular	events.	However,	the	rationale	for	shared	decision	making	is	not	
to	improve	compliance	with	clinical	or	public	health	priorities,	and	it	is	
to	achieve	a	decision	which	 is	 congruent	with	 the	patient’s	personal	
priorities,	values	and	beliefs.	This	potential	conflict	was	not	discussed	
in	the	study	reports.
5  | CONCLUSION
Hypertension	is	a	long-	term	condition	in	which	patients	and	their	cli-
nicians	frequently	face	choices	about	starting	or	modifying	hyperten-
sion	treatment.	Shared	decision	making	is	increasingly	advocated	for	
all	health-	care	choices,	including	those	taken	in	the	care	of	long-	term	
conditions.5	Decision	aids	continue	to	proliferate,48	and	front-	line	cli-
nicians	 have	 called	 for	more	 decision	 support	 interventions	 to	 help	
them	to	share	decisions	with	patients.	 In	this	study,	we	have	shown	
that	there	is	little	evidence	to	guide	a	choice	of	interventions	to	sup-
port	shared	decision	making	for	hypertension.
There	 is	 insufficient	 evidence	 to	 recommend	 how	 to	 support	
shared	 decision	 making	 for	 patients	 with	 hypertension	 in	 routine	
clinical	 care.	 Further	 studies	 are	 needed	 to	 develop	 and	 test	 in-
terventions	 able	 to	 support	 patients	 to	 share	 decisions	with	 their	
clinicians	and	which	can	be	 incorporated	 into	 routine	care.	Future	
research	should	make	explicit	the	underpinning	theory	of	the	inter-
vention’s	mechanism	of	effect	and	should	consider	using	observer-	
rated	measures	of	shared	decision	making.
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APPENDIX 1
Medline search strategy
Database:	Medline	1950	to	present
1. (shared	 decision*	 or	 sharing	 decision*	 or	 informed	 decision*	 or	
informed	 choice*	 or	 joint	 decision*).mp
2. ((share*	or	sharing	or	informed	or	participat*	or	support*)	adj2	(de-
cision*	or	decid*	or	choice*)).ti,ab
3. Or/1-2
4. Decision	 making/or	 Decision	 support	 techniques/or	 Decision	
Support	Systems,	Clinical/or	Choice	Behaviour/
5. ((decision*	or	choice*)	adj2	(making	or	support*	or	behaviour*	or	
aid*))ti,ab
6. Or/4-5
7. ((patient*	or	consumer*)	adj4	(involv*	or	participat*	or	enable*	or	
empower*	or	engage*	or	partner*)).ti,ab
8. Professional-patient	relations/
9. Nurse/or	physician/or	(nurse*or	physician*	or	clinician*	or	doctor*	
or	 general	 practitioner*	 or	 gp*	 or	 health	 care	 professional*	 or	
healthcare	 professional*	 or	 health	 care	 provider*	 or	 healthcare	
provider*	or	resident*).ti,ab
10. Patients/or	(patient*	or	consumer*	or	people*	or	individual*).ti,ab
11. 9 and 10
12. 11 or 8
13. Patient	participation/
14. 3	or	(6	and	7)	or	(6	and	12)	or	13
15. Exp	hypertension/
16. (hypertens*	or	antihypertens*).tw
17. ((high	or	elevat*	or	rais*)	adj2	blood	pressure).tw
18. Or/15-17
19. 14	and	18	The	following	steps	were	added	to	the	search	strategy	
for	the	search	update	in	September	2017	(the	initial	search	strate-
gies	 were	 used	 to	 concurrently	 identify	 studies	 for	 a	 qualitative	
synthesis):
20. intervention?.ti.	or	(intervention?	adj6	(clinician?	or	collaborat$	or	
community	or	complex	or	DESIGN$	or	doctor?	or	educational	or	
family	doctor?	or	 family	physician?	or	 family	practitioner?	or	 fi-
nancial	or	GP	or	general	practice?	or	hospital?	or	impact?	or	im-
prov$	 or	 individuali?e?	 or	 individuali?ing	 or	 interdisciplin$	 or	
multifacet$	 or	 multi-facet$	 or	 multimodal$	 or	 multi-modal$	 or	
personali?e?	 or	 personali?ing	 or	 pharmacies	 or	 pharmacist?	 or	
pharmacy	or	physician?	or	practitioner?	or	prescribe$	or	prescrip-
tion?	or	primary	care	or	professional$	or	provider?	or	regulatory	
or	regulatory	or	tailor$	or	target$	or	team$	or	usual	care)).ab.
21. (pre-intervention?	or	preintervention?	or	pre	intervention?	or	post-
intervention?	 or	 postintervention?	 or	 post	 intervention?). 
ti,ab.
22. (hospital$	or	patient?).hw.	and	(study	or	studies	or	care	or	health$	
or	practitioner?	or	provider?	or	physician?	or	nurse?	or	nursing	or	
doctor?).ti,hw.
23. Demonstration	project?.ti,ab.
24. (pre-post	or	pre	 test$	or	pretest$	or	posttest$	or	post	 test$	or	
(pre	adj5	post)).ti,ab.
25. (pre-workshop	 or	 post-workshop	 or	 (before	 adj3	 workshop)	 or	
(after	adj3	workshop)).ti,ab.
26. Trial.ti.	or	((study	adj3	aim?)	or	our	study).ab.
27. (before	adj10	(after	or	during)).ti,ab.
28. (quasi-experiment$	 or	 quasiexperiment$	 or	 quasi	 random$	 or	
quasirandom$	 or	 quasi	 control$	 or	 quasicontrol$	 or	 ((quasi$	 or	
experimental)	 adj3	 (method$	 or	 study	 or	 trial	 or	 design$))).
ti,ab,hw.
29. (time	series	adj2	interrupt$).ti,ab,hw.
30. (time	points	adj3	(over	or	multiple	or	3	or	4	or	5	or	6	or	7	or	8	or	9	
or	10	or	11	or	12	or	month$	or	hour?	or	day?	or	more	than)).ab.
31. Pilot.ti.
32. Pilot	projects/
33. (clinical	trial	or	controlled	clinical	trial	or	multicentre	study	or	ran-
domized	controlled	trial).pt.
34. (multicentre	or	multicenter	or	multi-centre	or	multi-center).ti.
35. Random$.ti,ab.	or	controlled.ti.
36. (control	adj3	(area	or	cohort?	or	compare?	or	condition	or	design	
or	group?	or	intervention?	or	participant?	or	study)).ab.
37. (control	year?	or	experimental	year?	or	(control	period?	or	experi-
mental	period?)).ti,ab.
38. Evaluation	studies	as	 topic/or	prospective	studies/or	 retrospec-
tive	studies/or	clinical	trials	as	topic/
39. (Utili?ation	or	programme	or	programmes).ti.
40. (during	adj5	period).ti,ab.
41. ((strategy	or	strategies)	adj2	(improv$	or	education$)).ti,ab.
42. (purpose	adj3	study).ab.
43. placebo.ab.
44. “comment	on”.cm.	or	review.pt.	or	(review	not	peer	review$).ti.
45. (rat	or	rats	or	cow	or	cows	or	chicken?	or	horse	or	horses	or	mice	or	
mouse	or	bovine	or	animal?).ti,hw.	or	veterinary$.ti,ab,hw.
46. exp	animals/not	humans.sh.
47. OR/20	-	43
48. OR/44-46
49. 47	NOT	48
